All In Biotech

Drug Trial Radar · NCT04840485

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase II/III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Active Ankylosing Spondylitis

Last checked: Nov 19, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 548 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

548

Actual

Start

Jun 9, 2021

Primary completion

Nov 3, 2023

Study completion Feb 28, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis

Conditions

  • Ankylosing Spondylitis

Interventions

  • SHR-1314Drug

    SHR-1314 high dose

  • SHR-1314Drug

    SHR-1314 low-dose

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Responded for Assessment of SpondyloArthritis international Society 20 Criteria (ASAS20) at 16 WeeksTime frame: 16 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.